These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 7203726)

  • 21. Tyrosine metabolism in patients with liver disease.
    Levine RJ; Conn HO
    J Clin Invest; 1967 Dec; 46(12):2012-20. PubMed ID: 6074004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endogenous nitric oxide production is augmented as the severity advances in patients with liver cirrhosis.
    Hori N; Okanoue T; Mori T; Kashima K; Nishimura M; Nanbu A; Yoshimura M; Takahashi H
    Clin Exp Pharmacol Physiol; 1996 Jan; 23(1):30-5. PubMed ID: 8713493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinetics of drug action in disease states. XIX. Effect of experimental liver disease on the neurotoxicity of theophylline in rats.
    Ramzan IM; Yasuhara M; Levy G
    J Pharmacol Exp Ther; 1987 Apr; 241(1):236-8. PubMed ID: 3494838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deranged metabolism of cyclic nucleotides in liver diseases.
    Matsushima T; Maekubo H; Yoshida T; Taneda H; Yoshida J; Miyazaki T; Okada F
    Horm Metab Res; 1985 Jun; 17(6):306-7. PubMed ID: 2991101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Protein-copper complex in primary biliary cirrhosis and other chronic diffuse diseases of the liver].
    Loginov AS; Aruin LI; Shepeleva SD
    Arkh Patol; 1980; 42(4):50-5. PubMed ID: 7396755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug disposition in liver disease.
    Shand DG
    N Engl J Med; 1977 Jun; 296(26):1527-8. PubMed ID: 865536
    [No Abstract]   [Full Text] [Related]  

  • 27. Disposition of caffeine and its metabolites in man.
    Tang-Liu DD; Williams RL; Riegelman S
    J Pharmacol Exp Ther; 1983 Jan; 224(1):180-5. PubMed ID: 6848742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hypnotics and sedatives in liver diseases (summary of session 4)].
    Z Gastroenterol Verh; 1976; (12):203-20. PubMed ID: 73293
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation.
    Yu SY; Chung HC; Kim EJ; Kim SH; Lee I; Kim SG; Lee MG
    J Pharm Pharmacol; 2002 Dec; 54(12):1687-92. PubMed ID: 12542900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Further evidence for the superiority of a 3-compartmental model for distribution analyses of i.v. injected bile acids in men: studies in patients with liver diseases.
    Klapdor R
    Acta Hepatogastroenterol (Stuttg); 1979 Feb; 26(1):23-5. PubMed ID: 425798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative hepatic phosphorus-31 magnetic resonance spectroscopy in compensated and decompensated cirrhosis.
    Corbin IR; Ryner LN; Singh H; Minuk GY
    Am J Physiol Gastrointest Liver Physiol; 2004 Aug; 287(2):G379-84. PubMed ID: 15191882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Diagnostic value of the study of caffeine elimination in chronic liver diseases].
    Darnót G; Nemesánszky E; Bariska J
    Orv Hetil; 1995 Apr; 136(18):927-32. PubMed ID: 7739851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Haptoglobin kinetics and enzyme activity in acute hepatitis, mechanical icterus and liver cirrhosis].
    Kallai L; Keler-Bacoka M; Blazkević K; Knĕzević S
    Cesk Gastroenterol Vyz; 1966 Sep; 20(6):398-407. PubMed ID: 5976469
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of water deprivation on the pharmacokinetics of theophylline and one of its metabolites, 1,3-dimethyluric acid, after intravenous and oral administration of aminophylline to rats.
    Choi HD; Kang HE; Chung HJ; Bae SK; Shin KN; Lee MG
    Biopharm Drug Dispos; 2007 Nov; 28(8):445-54. PubMed ID: 17847127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The metabolism of riboflavin in female patients with liver cirrhosis.
    Zempleni J; Galloway JR; McCormick DB
    Int J Vitam Nutr Res; 1996; 66(3):237-43. PubMed ID: 8899458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased thromboxane metabolites excretion in liver cirrhosis.
    Davì G; Ferro D; Basili S; Iuliano L; Camastra C; Giammarresi C; Santarone S; Rocca B; Landolfi R; Ciabattoni G; Cordova C; Violi F
    Thromb Haemost; 1998 Apr; 79(4):747-51. PubMed ID: 9569186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aminoacid imbalance ratio in liver disease.
    Maqsood R; Zuberi SJ
    J Pak Med Assoc; 1976 Jun; 26(6):145-6. PubMed ID: 826659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Aspects of cortisol metabolism in liver diseases].
    Della Casa L; Boni M
    Endocrinol Sci Cost; 1967 Nov; 29(5):344-53. PubMed ID: 5616116
    [No Abstract]   [Full Text] [Related]  

  • 39. Carnitine metabolism in patients with chronic liver disease.
    Krähenbühl S; Reichen J
    Hepatology; 1997 Jan; 25(1):148-53. PubMed ID: 8985281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Changes in thyroxine-binding capacity in liver diseases].
    Pottkämper G; Gatz J; Schwinn G; Hesch RD; Köbberling J
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 1():322-5. PubMed ID: 829382
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.